{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:53:50Z","timestamp":1790830430648,"version":"4.1.0"},"reference-count":42,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Huntington's Disease"],"published-print":{"date-parts":[[2020,9,25]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>No pharmacological treatment has been demonstrated to provide a functional benefit for persons with Huntington\u2019s disease (HD). Pridopidine is a sigma-1-receptor agonist shown to have beneficial effects in preclinical models of HD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To further explore the effect of pridopidine on Total Functional Capacity (TFC) in the recent double-blind, placebo-controlled PRIDE-HD study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We performed post-hoc analyses to evaluate the effect of pridopidine on TFC at 26 and 52 weeks. Participants were stratified according to baseline TFC score and analyzed using repeated measures (MMRM) and multiple imputation assuming missing not-at-random (MNAR) and worst-case scenarios.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The pridopidine 45 mg bid dosage demonstrated a beneficial effect on TFC for the entire population at week 52 of 0.87 (nominal p\u200a=\u200a0.0032). The effect was more pronounced for early HD participants (HD1\/HD2, TFC\u200a=\u200a7\u201313), with a change from placebo of 1.16 (nominal p\u200a=\u200a0.0003). This effect remained nominally significant using multiple imputation with missing not at random assumption as a sensitivity analysis. Responder analyses showed pridopidine 45 mg bid reduced the probability of TFC decline in early HD patients at Week 52 (nominal p\u200a=\u200a0.02).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Pridopidine 45 mg bid results in a nominally significant reduction in TFC decline at 52 weeks compared to placebo, particularly in patients with early-stage HD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3233\/jhd-200440","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T11:49:10Z","timestamp":1604663350000},"page":"371-380","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":28,"title":["Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study"],"prefix":"10.1177","volume":"9","author":[{"given":"Andrew","family":"McGarry","sequence":"first","affiliation":[{"name":"Cooper University Healthcare at Rowan University, Camden, NJ, USA"},{"name":"Clintrex Research Corporation, Sarasota, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Leinonen","sequence":"additional","affiliation":[{"name":"Clintrex Research Corporation, Sarasota, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Kieburtz","sequence":"additional","affiliation":[{"name":"Clintrex Research Corporation, Sarasota, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Geva","sequence":"additional","affiliation":[{"name":"Prilenia Therapeutics, Herzliya, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Warren","family":"Olanow","sequence":"additional","affiliation":[{"name":"Mount Sinai School of Medicine, New York City, NY, USA"},{"name":"Clintrex Research Corporation, Sarasota, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hayden","sequence":"additional","affiliation":[{"name":"Prilenia Therapeutics, Herzliya, Israel"},{"name":"Centre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,11,6]]},"reference":[{"key":"ref001","doi-asserted-by":"crossref","unstructured":"McGarryA, BiglanK, MarshallF. Huntington\u2019s disease. Rosenberg\u2019s Molecular and Genetic Basis of Neurological and Psychiatric Disease. London; Elsevier, 2015.","DOI":"10.1016\/B978-0-12-410529-4.00075-9"},{"key":"ref002","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphs.2014.12.005"},{"key":"ref003","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.08.036"},{"key":"ref004","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2012.09.007"},{"key":"ref005","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2010.07.023"},{"key":"ref006","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2012.3"},{"key":"ref007","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-015-3997-8"},{"key":"ref008","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.nbd.2016.10.006","volume":"97","author":"Ryskamp D","year":"2016","journal-title":"Neurobiol Dis"},{"issue":"18","key":"ref009","first-page":"3975","volume":"25","author":"Geva M","year":"2016","journal-title":"Hum Med Gen"},{"key":"ref010","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.05.009"},{"key":"ref011","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1038-15.2016"},{"key":"ref012","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.12604"},{"key":"ref013","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25362"},{"key":"ref014","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70233-2"},{"key":"ref015","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30391-0"},{"key":"ref016","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870110204"},{"key":"ref017","unstructured":"ShoulsonI, KurlanR, RubinAJ Assessment of functional capacity in neurodegenerative movement disorders: Huntington\u2019s disease as a prototype. In: Munsat TL, editors. Quantification of neurological deficit. Boston: Butterworths; 1989. pp. 271-283."},{"key":"ref018","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.3.397"},{"key":"ref019","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21181"},{"key":"ref020","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003478"},{"key":"ref021","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004209"},{"key":"ref022","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004743"},{"key":"ref023","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.2.452"},{"key":"ref024","unstructured":"ReilmannR, OlanowCW, McGarryA, GevaM, LeinonenM, HaydenM, et al. Novel PET data and analysis of early HD from PRIDE-HD. International Parkinson and Movement Disorder Society Congress, Nice, France, September 2-26, 2019."},{"key":"ref025","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145708008547"},{"key":"ref026","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(94)91397-8"},{"key":"ref027","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-5846(96)00160-1"},{"key":"ref028","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0173(01)00112-6"},{"key":"ref029","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.CR0050032"},{"key":"ref030","doi-asserted-by":"publisher","DOI":"10.1007\/BF02247374"},{"key":"ref031","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(94)90298-4"},{"key":"ref032","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(90)90186-A"},{"key":"ref033","doi-asserted-by":"publisher","DOI":"10.1007\/BF00167567"},{"key":"ref034","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.CRJ04005X"},{"key":"ref035","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(24)39299-7"},{"key":"ref036","doi-asserted-by":"publisher","DOI":"10.1002\/syn.20069"},{"key":"ref037","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2003.12.018"},{"key":"ref038","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.14723"},{"key":"ref039","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-018-00699-9"},{"key":"ref040","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(99)80011-X"},{"key":"ref041","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-832680"},{"key":"ref042","unstructured":"The Voice of the Patient: Huntington\u2019s Disease. https:\/\/www.fda.gov\/media\/96196\/download"}],"container-title":["Journal of Huntington's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JHD-200440","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/JHD-200440","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JHD-200440","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:51:08Z","timestamp":1777452668000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/JHD-200440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,25]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,9,25]]}},"alternative-id":["10.3233\/JHD-200440"],"URL":"https:\/\/doi.org\/10.3233\/jhd-200440","relation":{},"ISSN":["1879-6397","1879-6400"],"issn-type":[{"value":"1879-6397","type":"print"},{"value":"1879-6400","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,25]]}}}